Anti-Diabetic Therapies and Cancer: From Bench to Bedside DOI Creative Commons
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela

и другие.

Biomolecules, Год журнала: 2024, Номер 14(11), С. 1479 - 1479

Опубликована: Ноя. 20, 2024

Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention its potential anti-cancer effects, primarily through modulation AMP-activated protein kinase/mammalian target rapamycin (AMPK/mTOR) pathway and induction autophagy. Beyond metformin, other conventional treatments, such as insulin, sulfonylureas (SUs), pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, have also been examined their roles in biology, though findings are often inconclusive. More recently, novel medications, like glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) sodium-glucose co-transporter-2 (SGLT-2) revolutionized DM management by not only improving glycemic control but delivering substantial cardiovascular renal benefits. Given diverse metabolic including anti-obesogenic properties, agents now under meticulous investigation influence tumorigenesis advancement. This review aims to offer comprehensive exploration evolving landscape glucose-lowering treatments implications biology. It critically evaluates experimental evidence surrounding molecular mechanisms which medications may modulate oncogenic signaling pathways reshape tumor microenvironment (TME). Furthermore, it assesses translational research clinical trials gauge practical relevance real-world settings. Finally, explores adjuncts treatment, particularly enhancing efficacy chemotherapy, minimizing toxicity, addressing resistance within framework immunotherapy.

Язык: Английский

Identification of PLAC1 as a prognostic biomarker and molecular target in clear cell renal cell carcinoma DOI Creative Commons
Ying Kong,

Zongming Jia,

Yizhang Sun

и другие.

Cellular Signalling, Год журнала: 2025, Номер 127, С. 111606 - 111606

Опубликована: Янв. 13, 2025

Clear cell renal carcinoma (ccRCC) is a common clinical tumor of the urinary system. The lack effective diagnostic and treatment options poses serious challenge to treatment. Therefore, identifying molecular targets has become one potential means treat this disease. Firstly, analysis TCGA database found that PLAC1 was abnormally highly expressed in ccRCC negatively correlated with patient prognosis. Western blotting immunofluorescence experiments further verified patients, knockdown inhibited development vitro. Last, high-throughput virtual screening technology (HTVS) performed identify two inhibitors ，AmB Cana, which were able reduce expression progression ccRCC. In conclusion, current investigation indicated could serve as prognostic biomarker, AmB Cana inhibit by reducing PLAC1, making it therapeutic option for

Язык: Английский

Процитировано

1
Impact of SGLT2 Inhibitors on Survival in Gastrointestinal Cancer Patients Undergoing Chemotherapy and/or Radiotherapy: A Real-World Data Retrospective Cohort Study DOI Open Access
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Янв. 12, 2025

Abstract Background The role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) drugs in the management diabetes and cardiovascular disease is well-established, but emerging evidence suggests potential effects on cancer outcomes, including gastrointestinal (GI) cancers. We conducted an extensive, sex-oriented, real-world data analysis to investigate whether SGLT2i can enhance GI outcomes when used alongside standard therapies such as chemotherapy radiotherapy. Methods study applied a retrospective cohort design with from TriNetX research database ( https://trinetx.com ), examining patients treated and/or radiotherapy between 2013 2023. intervention consisted Gl who received SGLT2i, while control did not. A 5-year follow-up period was used, baseline characteristics were balanced using 1:1 propensity score matching technique. Cox proportional-hazards logistic regression models assessed mortality morbidity risks cohorts. Results included 6,389 male 3,457 female (ICD-10: C15-C25). use significantly associated improved survival for both (HR 0.568; 95% CI 0.534-0.605) 0.561; 0.513-0.614) undergoing also correlated lower hospitalisation rates (OR 0.684; 0.637-0.734) (OR, 0.590; 0.536-0.650) patients. subtypes demonstrated similar benefits, without significant adverse effects. Conclusions Repurposing SGLT2 inhibitors treatment could potentially improve causing side Further clinical trials are needed confirm these findings establish optimal condition its application treatment.

Язык: Английский

Процитировано

0
Impact of SGLT2 inhibitors on survival in gastrointestinal cancer patients undergoing chemotherapy and/or radiotherapy: a real-world data retrospective cohort study DOI Creative Commons
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya

и другие.

BMC Cancer, Год журнала: 2025, Номер 25(1)

Опубликована: Март 25, 2025

The role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) drugs in the management diabetes and cardiovascular disease is well-established, but emerging evidence suggests potential effects on cancer outcomes, including gastrointestinal (GI) cancers. We conducted an extensive, sex-oriented, real-world data analysis to investigate whether SGLT2i can enhance GI outcomes when used alongside standard therapies such as chemotherapy radiotherapy. study applied a retrospective cohort design with from TriNetX research database ( https://trinetx.com ), examining patients treated and/or radiotherapy between 2013 2023. intervention consisted Gl who received SGLT2i, while control did not. A 5-year follow-up period was used, baseline characteristics were balanced using 1:1 propensity score matching technique. Cox proportional-hazards logistic regression models assessed mortality morbidity risks cohorts. included 6,389 male 3,457 female (ICD-10: C15-C25). use significantly associated improved survival for both (HR 0.568; 95% CI 0.534–0.605) 0.561; 0.513–0.614) undergoing also correlated lower hospitalisation rates (OR 0.684; 0.637–0.734) (OR, 0.590; 0.536–0.650) patients. subtypes demonstrated similar benefits, without significant adverse effects. Repurposing SGLT2 inhibitors treatment could potentially improve causing side Further clinical trials are needed confirm these findings establish optimal condition its application treatment.

Язык: Английский

Процитировано

0
Insights on metabolic connections and interplay between cancer and diabetes: role of multi-target drugs DOI Creative Commons
Angeline Julius,

Suresh Malakondaiah,

Raghu Babu Pothireddy

и другие.

Deleted Journal, Год журнала: 2025, Номер 2(1)

Опубликована: Март 26, 2025

Язык: Английский

Процитировано

0
Obesity-Associated Colorectal Cancer DOI Open Access
Lucía G. Gutiérrez, Omar Motiño, Daniel Barriuso

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(16), С. 8836 - 8836

Опубликована: Авг. 14, 2024

Colorectal cancer (CRC) affects approximately 2 million people worldwide. Obesity is the major risk factor for CRC. In addition, obesity contributes to a chronic inflammatory stage that enhances tumor progression through secretion of proinflammatory cytokines. addition an increased response, obesity-associated presents accrued molecular factors related characteristics, such as genome instability, sustained cell proliferation, telomere dysfunctions, angiogenesis, and microbial alteration, among others. Despite evidence accumulated over last few years, treatments CRC do not differ from in normal-weight individuals. this review, we summarize current knowledge on cancer, including its epidemiology, factors, treatments. Finally, enumerate possible new therapeutic targets may improve conditions obese patients. key development CRC, resulting reversal should be considered strategy improving antineoplastic therapies.

Язык: Английский

Процитировано

2
Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3/Nurr1/GSK-3β/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats DOI

Ahmed M Abdelaziz,

Nora O. Abdel Rasheed,

Hala F. Zaki

и другие.

International Immunopharmacology, Год журнала: 2024, Номер 146, С. 113839 - 113839

Опубликована: Дек. 18, 2024

Язык: Английский

Процитировано

1
S100A8 knockdown activates the PI3K/AKT signaling pathway to inhibit microglial autophagy and improve cognitive impairment mediated by chronic sleep deprivation DOI Creative Commons
Yanhong Xiong,

Weidong Liang,

Xifeng Wang

и другие.

International Immunopharmacology, Год журнала: 2024, Номер 143, С. 113375 - 113375

Опубликована: Окт. 16, 2024

Cognitive dysfunction is one of the major symptoms chronic sleep deprivation (CSD). Abnormal autophagy and apoptosis are thought to be important mechanisms. S100 Calcium Binding Protein A8 (S100A8) plays a key role in microglia. This study investigated whether S100A8 knockdown can effectively inhibit aberrant microglia improve cognitive function by activating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway under CSD conditions.

Язык: Английский

Процитировано

0
Research Progress of Sodium-Glucose Co-Transporter Protein-2 Inhibitors in Lung Cancer DOI

晓倩 林

Advances in Clinical Medicine, Год журнала: 2024, Номер 14(10), С. 1375 - 1381

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

0
Anti-Diabetic Therapies and Cancer: From Bench to Bedside DOI Creative Commons
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela

и другие.

Biomolecules, Год журнала: 2024, Номер 14(11), С. 1479 - 1479

Опубликована: Ноя. 20, 2024

Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention its potential anti-cancer effects, primarily through modulation AMP-activated protein kinase/mammalian target rapamycin (AMPK/mTOR) pathway and induction autophagy. Beyond metformin, other conventional treatments, such as insulin, sulfonylureas (SUs), pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, have also been examined their roles in biology, though findings are often inconclusive. More recently, novel medications, like glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) sodium-glucose co-transporter-2 (SGLT-2) revolutionized DM management by not only improving glycemic control but delivering substantial cardiovascular renal benefits. Given diverse metabolic including anti-obesogenic properties, agents now under meticulous investigation influence tumorigenesis advancement. This review aims to offer comprehensive exploration evolving landscape glucose-lowering treatments implications biology. It critically evaluates experimental evidence surrounding molecular mechanisms which medications may modulate oncogenic signaling pathways reshape tumor microenvironment (TME). Furthermore, it assesses translational research clinical trials gauge practical relevance real-world settings. Finally, explores adjuncts treatment, particularly enhancing efficacy chemotherapy, minimizing toxicity, addressing resistance within framework immunotherapy.

Язык: Английский

Процитировано

0